| Convergent antibody responses to SARS-CoV-2 in convalescent individuals DF Robbiani, C Gaebler, F Muecksch, JCC Lorenzi, Z Wang, A Cho, ... Nature 584 (7821), 437-442, 2020 | 2104 | 2020 |
| Evolution of antibody immunity to SARS-CoV-2 C Gaebler, Z Wang, JCC Lorenzi, F Muecksch, S Finkin, M Tokuyama, ... Nature 591 (7851), 639-644, 2021 | 1811 | 2021 |
| mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants Z Wang, F Schmidt, Y Weisblum, F Muecksch, CO Barnes, S Finkin, ... Nature 592 (7855), 616-622, 2021 | 1540 | 2021 |
| Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants Y Weisblum, F Schmidt, F Zhang, J DaSilva, D Poston, JCC Lorenzi, ... elife 9, e61312, 2020 | 1532 | 2020 |
| Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies CO Barnes, AP West, KE Huey-Tubman, MAG Hoffmann, NG Sharaf, ... Cell 182 (4), 828-842. e16, 2020 | 811 | 2020 |
| Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection Z Wang, F Muecksch, D Schaefer-Babajew, S Finkin, C Viant, C Gaebler, ... Nature 595 (7867), 426-431, 2021 | 789 | 2021 |
| Vaccine breakthrough infections with SARS-CoV-2 variants E Hacisuleyman, C Hale, Y Saito, NE Blachere, M Bergh, EG Conlon, ... New England Journal of Medicine 384 (23), 2212-2218, 2021 | 788 | 2021 |
| Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses F Schmidt, Y Weisblum, F Muecksch, HH Hoffmann, E Michailidis, ... Journal of Experimental Medicine 217 (11), 2020 | 599 | 2020 |
| Plasma neutralization of the SARS-CoV-2 Omicron variant F Schmidt, F Muecksch, Y Weisblum, J Da Silva, E Bednarski, A Cho, ... New England Journal of Medicine 386 (6), 599-601, 2022 | 476 | 2022 |
| Enhanced SARS-CoV-2 neutralization by dimeric IgA Z Wang, JCC Lorenzi, F Muecksch, S Finkin, C Viant, C Gaebler, ... Science translational medicine 13 (577), eabf1555, 2021 | 471 | 2021 |
| Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies AJ Greaney, TN Starr, CO Barnes, Y Weisblum, F Schmidt, M Caskey, ... Nature communications 12 (1), 4196, 2021 | 388 | 2021 |
| Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo A Schäfer, F Muecksch, JCC Lorenzi, SR Leist, M Cipolla, S Bournazos, ... Journal of Experimental Medicine 218 (3), e20201993, 2020 | 343 | 2020 |
| Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination A Cho, F Muecksch, D Schaefer-Babajew, Z Wang, S Finkin, C Gaebler, ... Nature 600 (7889), 517-522, 2021 | 286 | 2021 |
| Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients F Muecksch, H Wise, B Batchelor, M Squires, E Semple, C Richardson, ... The Journal of infectious diseases 223 (3), 389-398, 2021 | 281 | 2021 |
| Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations F Muecksch, Y Weisblum, CO Barnes, F Schmidt, D Schaefer-Babajew, ... Immunity 54 (8), 1853-1868. e7, 2021 | 268 | 2021 |
| Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost F Muecksch, Z Wang, A Cho, C Gaebler, T Ben Tanfous, J DaSilva, ... Nature 607 (7917), 128-134, 2022 | 265 | 2022 |
| Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants J Xu, K Xu, S Jung, A Conte, J Lieberman, F Muecksch, JCC Lorenzi, ... Nature 595 (7866), 278-282, 2021 | 203 | 2021 |
| Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients LL Luchsinger, BP Ransegnola, DK Jin, F Muecksch, Y Weisblum, W Bao, ... Journal of clinical microbiology 58 (12), 10.1128/jcm. 02005-20, 2020 | 184 | 2020 |
| Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice R De Gasparo, M Pedotti, L Simonelli, P Nickl, F Muecksch, I Cassaniti, ... Nature 593 (7859), 424-428, 2021 | 136 | 2021 |
| Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies CA Jette, AA Cohen, PNP Gnanapragasam, F Muecksch, YE Lee, ... Cell reports 36 (13), 2021 | 121 | 2021 |
